Response Biomedical audits sales to 'terrorist' states; AngioDynamics closes $355M Navilyst deal;

 @MarkHFierce: Folks, there's still time to submit your nominations for the FierceMedicalDevices Fierce 15 private device developers. Survey | Follow @MarkHFierce

> Devicemaker AngioDynamics ($ANGO) has completed its $355 million purchase of Navilyst Medical. Story

> Response Biomedical ($RSB) has launched an internal audit of its sales in response to SEC concerns about device companies selling tech to "state sponsors of terrorism," including Iran. News

> ActiViews gained Chinese regulatory approval to start marketing its CT-Guide navigation in the world's most populous country for minimally invasive diagnostic and therapeutic procedures. Story

> Spain's Andago has received a CE mark for its mobile patient-monitoring device, Carefy, which allows physicians to keep tabs on patients remotely. More

> Germany's MagForce has signed a distribution deal with a Russian company, hoping to get its NanoThermR tumor-killing device on the market in that country and, eventually, across the globe. Release

> Misonix ($MSON) is targeting the emerging Baltic market with a distribution deal for its surgical devices, allowing Lithuania's Apex Medicus to market its products in the region. Story

> Greatbatch, which makes medical device technologies for cardiac, neurology, vascular and orthopedic markets, plans to move its headquarters from Clarence, NY to Frisco, TX. Release

Biotech News

 @FierceBiotech: New strategy from researchers at Penn State reactivates genes to suppress cancer. More | Follow @FierceBiotech

 @JohnCFierce: Pfizer sent me their take on tafamidis just now. No retreat, no surrender. Updated story | Follow @JohnCFierce

 @RyanMFierce: Survey says building "electronic" trials is painfully slow, but that's true for most all clinical trials. More | Follow @RyanMFierce

> In rare slap, FDA review rips up Pfizer's case for tafamidis. More

> Biotechs raise new VC rounds to back inhalable drugs, antimicrobials. Article

> Takeda shutters Bay Area R&D shop in California shakeup. News

> Lilly posts clean safety data on PhIII diabetes blockbuster hopeful. Story

Pharma News

 @FiercePharma: J&J's Simponi beat placebo at fighting colitis symptoms, study finds. Possible new use with 700,000 cases, WSJ says. More |  Follow @FiercePharma

> Pharma dealmakers, the price is right for Sweden's Meda. Story

> Private equity owner seeks $510M-plus deal for Germany's Aenova. News

> Bayer's Nexavar falters in another lung cancer trial. Article

Pharma Manufacturing News

> FDA inspectors cite problems at Impax California plant. News

> Funding would allow FDA to target more foreign plants. More

> Chinese court favors J&J in distribution fight. Article

Biotech Research News

> Malaria's genetic secrets open door to new drug targets. Story

> Celery extract shrinks difficult breast cancer tumor in mouse trials. Article

> New strategy reactivates genes to suppress cancer. Report

> Researchers find novel way to treat anxiety. More

> Gene therapy = fountain of youth in mice. Item

And Finally... Many premature babies lack the neurological ability to suck and feed, so doctors at the University of Florida have developed the Pacifier Activated Lullaby, a device that teaches babies how to feed and has proven to lower hospital stays by 5 days. Report

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.